Cargando…
Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population
Major lacunae exist in our understanding of how developmental changes in drug biotransformation influence drug’s exposure and thus its efficacy and toxicity in children. It is not just about smaller weight in children, which modifies the pattern of the drug's exposure. There are developmental,...
Autores principales: | Uppugunduri, Chakradhara Rao S., Ansari, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405624/ https://www.ncbi.nlm.nih.gov/pubmed/26908134 http://dx.doi.org/10.2174/1872312810666160224143443 |
Ejemplares similares
-
Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use †
por: Mlakar, Vid, et al.
Publicado: (2016) -
Pediatric Therapeutic Drug Monitoring for Selective Serotonin Reuptake Inhibitors
por: Strawn, Jeffrey R., et al.
Publicado: (2021) -
Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response
por: Kamath, Ashwin, et al.
Publicado: (2022) -
A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation
por: Robin, Shannon, et al.
Publicado: (2022) -
Correction to: A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation
por: Robin, Shannon, et al.
Publicado: (2022)